Primary * To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose * To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral dose in healthy male subjects * To investigate the safety of LCB01-0371 after a multiple oral dose in healthy male subjects
* To investigate the PK characteristics of LCB01-0371 after a multiple oral dose * To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Asan Medical Center
Seoul, South Korea
Number of participants with adverse events
Time frame: Up to 7 days
Area under the plasma concentration versus time curve (AUC) of LCB01-0371
Time frame: Up to 7 days
Peak Plasma Concentration (Cmax) of LCB01-0371
Time frame: Up to 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.